Orexin B (also called hypocretin-2) is a wake-promoting neuropeptide studied mainly in sleep, arousal, and appetite research. This page describes hypothesized and investigational effects, not established treatments.
Overview
Orexin B is the second of two orexin peptides made by neurons in the lateral hypothalamus. It preferentially activates the OX2R receptor and participates in the brain systems that maintain wakefulness. Because of this role, most interest in orexin B centres on:
- OX2R-biased signalling within arousal circuits.
- Its contribution to maintaining wakefulness alongside orexin A.
- Its links to appetite and energy balance.
These are the mechanisms researchers study; they are not a promise of any specific cognitive, cosmetic, or clinical result.
OX2R selectivity and wakefulness
The most discussed feature of orexin B is its preference for the OX2R receptor, which is closely associated with the stabilisation of wakefulness. This makes orexin B a useful research tool for probing OX2R-specific contributions to arousal.
- OX2R is strongly linked to sustaining a stable wake state.
- Orexin B's receptor bias helps researchers isolate OX2R-driven effects.
- Any observed effect depends on delivery, stability, and the individual.
Appetite and arousal
Because orexin neurons connect arousal to motivated behaviour, orexin B is also discussed in relation to appetite and energy balance. As part of the same system as orexin A, it is thought to contribute to feeding and arousal pathways, though the applied evidence for giving orexin B to influence these outcomes is limited and does not amount to a proven benefit.
How orexin B compares to orexin A
Orexin B is best understood by contrast with its sibling peptide, orexin A:
- Receptor profile — orexin B favours OX2R, whereas orexin A activates both OX1R and OX2R.
- Stability — orexin B is shorter-lived and less chemically stable than orexin A.
- Study depth — orexin B is the less extensively investigated of the two.
The OX2R selectivity and lower stability are the two features that most clearly set orexin B apart from orexin A.
Evidence and caveats
Orexin B has a defined place in arousal biology, but that is not the same as proven benefit from giving it as a peptide. Key caveats:
- It is not an FDA-approved therapy in the United States.
- Its lower stability adds practical uncertainty to research findings.
- The evidence base is thinner than for orexin A.
- Long-term safety in healthy people has not been established.